P&G Hygiene FY26 net profit rises 19% to ₹857 crore
P&G Hygiene reported a 19% rise in FY26 net profit to ₹857 crore, with sales at ₹4,290 crore. The board recommended a total dividend of ₹255 per share.
*this image is generated using AI for illustrative purposes only.
Procter & Gamble Hygiene and Health Care Limited reported a 19% increase in net profit to ₹857 crore for the fiscal year ended March 31, 2026, driven by product mix, productivity, and efficiency. Sales for the year stood at ₹4,290 crore, remaining flat compared to the indexed comparable period. The board has recommended a total dividend of ₹255 per share, comprising a final dividend of ₹60 and an interim dividend of ₹195, subject to shareholder approval.
The company changed its financial year end from June 30 to March 31 effective last year, resulting in the previous financial year covering a nine-month period from July 1, 2024, to March 31, 2025. Consequently, the current year's performance is indexed against the comparable 12-month period in the prior year to ensure accurate assessment.
Q4 Financial Performance
For the fourth quarter ended March 31, 2026, revenue stood at ₹941 crore compared to ₹992 crore in the same period last year, reflecting a decline. Net profit for the quarter came in at ₹153 crore versus ₹156 crore year-on-year. Despite the revenue pressure, EBITDA improved on a year-on-year basis, rising to ₹217 crore from ₹211 crore, while the EBITDA margin expanded to 23.1% from 21.24% in the same period last year, reflecting improved operational efficiency.
The following table summarises the key Q4 metrics:
| Metric: | Q4 FY26 | Q4 FY25 (YoY) |
|---|---|---|
| Revenue: | ₹941 crore | ₹992 crore |
| Net Profit: | ₹153 crore | ₹156 crore |
| EBITDA: | ₹217 crore | ₹211 crore |
| EBITDA Margin: | 23.1% | 21.24% |
Full-Year Financial Performance
The company's earnings per share (EPS) for the year increased to ₹263.86 from ₹196.11 in the prior period. Total comprehensive income for FY26 was ₹861 crore. Cash and cash equivalents as of March 31, 2026, stood at ₹5,570 crore, compared to ₹4,664 crore a year ago. The table below presents the full-year financial summary:
| Financial Metric (₹ in Lakhs): | Year Ended March 31, 2026 | Previous Year (9 Months) Ended March 31, 2025 |
|---|---|---|
| Revenue from operations: | 4,29,042 | 3,37,442 |
| Total income: | 4,33,289 | 3,41,176 |
| Total expenses: | 3,16,626 | 2,54,960 |
| Profit before tax: | 1,16,663 | 86,216 |
| Profit for the period: | 85,650 | 63,659 |
| Earnings per share (Basic) (₹): | 263.86 | 196.11 |
Strategic Initiatives
V Kumar, Managing Director, emphasized the company's focus on meaningful innovation across its feminine care and healthcare portfolios. During the year, the company amplified communication for the Whisper Period Panty and upgraded formulations for Whisper Choice and Whisper Bindazzz Nights. In healthcare, the upgraded Vicks VapoRub formulation with Eucalyptus Oil, Menthol, and Camphor continued to deliver All-Night Relief.
Dividend Declaration
The board recommended a final dividend of ₹60 per equity share of face value ₹10 each. Including the interim dividend of ₹195 per share, the total payout for the fiscal amounts to ₹255 per share. The final dividend is scheduled to be paid on or before September 18, 2026, pending approval by members at the 62nd Annual General Meeting.
Historical Stock Returns for P&G Hygiene and Health Care
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.59% | +0.31% | -6.39% | -24.48% | -32.19% | -27.45% |
How does the company plan to address the revenue decline observed in Q4 to drive top-line growth in the upcoming fiscal year?
What specific strategic innovations are in the pipeline for the feminine care and healthcare portfolios to sustain margin expansion?
With cash reserves rising to ₹5,570 crore, is the company considering acquisitions or increased capital expenditure to fuel future growth?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
